Skip to main content
Amoy Diagnostics Co.,Ltd. logo

Amoy Diagnostics Co.,Ltd. — Investor Relations & Filings

Ticker · 300685 ISIN · CNE1000034D3 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,090 across all filing types
Latest filing 2018-04-02 Audit Report / Informat…
Country CN China
Listing Shenzhen Stock Exchange 300685

About Amoy Diagnostics Co.,Ltd.

https://www.amoydx.com

Amoy Diagnostics Co., Ltd. specializes in the development and commercialization of molecular diagnostic products for precision oncology. The company provides a comprehensive portfolio of testing kits designed to identify genetic mutations and biomarkers essential for personalized cancer treatment. Its core technology platforms include the proprietary ADx-ARMS, Super-ARMS, and specialized Next-Generation Sequencing (NGS) solutions. AmoyDx focuses on companion diagnostics (CDx), collaborating extensively with global pharmaceutical companies to integrate diagnostic testing into clinical drug development and patient management. Key products cover a wide range of solid tumors, including lung, colorectal, and breast cancers, facilitating targeted therapy selection and monitoring. The company maintains rigorous quality standards, with numerous products receiving regulatory approvals for clinical use in multiple international markets.

Recent filings

Filing Released Lang Actions
中信证券股份有限公司关于公司2017年度募集资金存放与使用情况的专项核查报告
Audit Report / Information Classification · 95% confidence The document is titled as a "专项核查报告" (special inspection report) by 中信证券股份有限公司 regarding the 2017 annual fundraising funds deposit and usage situation of 厦门艾德生物医药科技股份有限公司. It details the actual fundraising amount, usage, balance, and management of the funds raised from the company's IPO in 2017. It includes detailed financial figures, bank account information, and audit opinions from an accounting firm. The document is a specialized audit or verification report focusing on the use and management of raised funds, not a full annual report or earnings release. It is not a simple announcement or publication notice but contains substantive financial and audit information. This fits the definition of an Audit Report / Information (AR) as it is a standalone audit-related report on fundraising usage and compliance, separate from the full annual report. FY 2017
2018-04-02 Chinese
独立董事关于相关事项的事前认可意见
Regulatory Filings Classification · 95% confidence The document is a statement from independent directors providing prior approval opinions regarding the reappointment of the 2018 audit firm for the company. It references regulatory guidelines and the company's internal rules but does not contain any financial data or audit results itself. The document is short (446 characters) and serves as an announcement or opinion related to audit matters rather than a full audit report. Therefore, it is best classified as a Regulatory Filing (RNS), which covers miscellaneous regulatory announcements that do not fit other categories.
2018-04-02 Chinese
第一届监事会第十一次会议决议公告
Regulatory Filings Classification · 95% confidence The document is a resolution announcement from the Supervisory Board of Xiamen Aide Biomedical Technology Co., Ltd. It details the approval of various reports related to the 2017 fiscal year, including the Supervisory Board's work report, the 2017 annual report and its summary, the 2017 financial statements audited by an accounting firm, the 2017 profit distribution plan, and other related reports. The document also mentions that these reports are published on the designated disclosure website and that the resolutions will be submitted to the 2017 annual shareholders' meeting for approval. The document length is 3272 characters, which is relatively short and mainly serves as a meeting resolution announcement rather than the full annual report itself. It references the annual report and financial statements but does not contain the full financial data or detailed analysis. Therefore, according to the "Menu vs Meal" rule, this document is an announcement of the Supervisory Board meeting resolutions and approvals related to the annual report, not the annual report itself. This fits best under the category of Regulatory Filings (RNS), which is the fallback for miscellaneous regulatory announcements that do not fit other categories. Hence, the classification is RNS with high confidence.
2018-04-02 Chinese
中信证券股份有限公司关于公司2017年年度跟踪报告
Audit Report / Information Classification · 95% confidence The document is titled as a "2017 年年度跟踪报告" which translates to "2017 Annual Tracking Report" for Xiamen Aide Biomedical Technology Co., Ltd., prepared by CITIC Securities Co., Ltd. It includes detailed sections on sponsorship work overview, company and shareholder commitment fulfillment, issues found and measures taken, and other matters related to regulatory compliance and corporate governance. The document contains substantive content about company operations, compliance, and governance over the year 2017. It is not a brief announcement or a certification letter but a comprehensive report on the company's annual tracking status by the sponsor. This aligns with the category of an Annual Report or similar comprehensive yearly report. However, since it is a sponsor's annual tracking report rather than the company's own full annual report (10-K), and it focuses on audit, compliance, and regulatory oversight aspects, it fits best under Audit Report / Information (AR). The document is lengthy (over 13,000 characters) and contains detailed substantive information, not just an announcement or summary. Therefore, the most appropriate classification is AR (Audit Report / Information). FY 2017
2018-04-02 Chinese
关联方占用资金情况的专项审计说明（2017年度）
Audit Report / Information Classification · 95% confidence The document is a specialized audit report focusing on the 2017 non-operating funds occupation and related party transactions of Xiamen Aide Biomedical Technology Co., Ltd. It includes an auditor's opinion, references to regulatory requirements by the China Securities Regulatory Commission, and detailed financial tables related to related party funds. The document is titled as a "专项审计说明" (special audit explanation) and contains audit procedures, responsibilities, and conclusions. It is not a full annual report, nor an earnings release or management discussion. It is a standalone audit report on a specific issue, consistent with the definition of Audit Report / Information (AR). The document length is under 5,000 characters but contains substantive audit content and financial data, so it is not merely an announcement or certification. Therefore, the correct classification is AR with high confidence. FY 2017
2018-04-02 Chinese
中信证券股份有限公司关于公司2017年度内部控制自我评价报告的核查意见
Audit Report / Information Classification · 95% confidence The document is titled as an internal control self-evaluation report for the year 2017 of Xiamen Aide Biomedical Technology Co., Ltd., with verification opinions from CITIC Securities Co., Ltd. It discusses the company's internal control systems, governance structure, risk assessment, control activities, and evaluation conclusions. The content is detailed and comprehensive, covering internal control evaluation procedures and results, which aligns with an Audit Report or Information document rather than a full Annual Report or other categories. It is not a brief announcement or a certification letter but a substantive report on internal controls. Therefore, the document fits best under the Audit Report / Information (AR) category. FY 2017
2018-04-02 Chinese

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.